TrialJournal of substance abuse treatment2022

Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.

Ali Jalali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.